Market Overview

Valeant Investors Should Wait And See What Happens, Scotiabank Says

Share:
Related VRX
Attention Biotech Investors: February PDUFA Catalysts Come Calling
42 Biggest Movers From Yesterday
Teva: Berkshire Thinks Bondholders Are 'Mullet Mullet' (Seeking Alpha)

Valeant Pharmaceuticals Intl Inc (NYSE: VRX) investors should take a wait and see approach, an analyst said on Monday. According to Scotiabank's Alan Ridgeway, anyone on the fence should "wait and see how the next few months play out."

Ridgeway holds a Sector Perform and a $42 price target on the stock.

The analyst also analyzed new TRx data from Valeant. TRx count is about 80 percent of October 2015 levels, while ophthalmology TRx count is near levels when the program began. Valeant's Jublia and Solodyn were down slightly from a week before, but Jublia's main competitor did fall further -- 17 percent -- last week.

Scotiabank also discussed Valeant's Walgreens-related issues. "[W]e believe the economics of the Walgreens deal and potential pricing concessions being negotiated with managed care for VRX's main brand products Jublia and Xifaxan are headwinds for VRX in 2016," he wrote.

"That said, it is early in the process on both fronts and we will continue to look for longer term changes in volume trends that may develop over time."

Latest Ratings for VRX

DateFirmActionFromTo
Jan 2018Goldman SachsInitiates Coverage OnSell
Dec 2017JP MorganDowngradesNeutralUnderweight
Nov 2017Deutsche BankMaintainsHold

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Ridgeway ValeantAnalyst Color Long Ideas Health Care Analyst Ratings Trading Ideas General

 

Related Articles (VRX)

View Comments and Join the Discussion!